As noted in the STORE 2024 Manual and SEER Manual, valid values are based on year of diagnosis. Pay close attention to these specific instructions.

2024:  For cases diagnosed January 1, 2024 and forward, The site-specific surgery codes are taken from Appendix C of the 2024 SEER Program Coding and Staging Manual, which is based on Appendix A of the ACoS STORE Manual -revised 2024.  The surgery codes are identical to STORE but the SEER appendix also contains supplementary annotations, including coding guidelines, solid tumor rules, EOD schemas, and additional instructions including site-specific codes for Neoadjuvant Therapy Treatment Effect. It can be found at: https://seer.cancer.gov/manuals/2024/appendixc.html

  • The site-specific surgery codes for Lung (C34._), Pancreas (C25._), Thyroid (C73._), Colon (C18._), and Breast (C50._) are updated to align with the Synoptic Operative Report for cases diagnosed January 1, 2024 and forward.

    • RX Hosp- and RX Summ-Recon Breast: CoC added two new data items, RX Hosp-Recon Breast [751] and RX Summ-Recon Breast [1335] for cases diagnosed on or after January 1, 2024. For diagnosis years 2022 and 2023, CoC collected these data in RX Hosp-Recon Breast [10106] and RX Summ-Recon Breast [10107].

  • To download the 2024 STORE Manual or historic STORE Manuals, visit: https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/ncdb-call-for-data/registry-manuals/
  • Quick reference for anyone reviewing surgery codes over time (2024): RX-Summ-Surg-Prim-Site-2024-Tables.xlsx

Surgery Codes Crosswalk 2024:  

When significant changes are made to the surgery codes, surgery code definitions, and/or instructions for assigning surgery codes for a site, a crosswalk is developed to assist with analyses and quality control reviews of surgery codes over time. They should not be used by registrars to directly code cancer cases.

These crosswalks are developed as an aid to anyone comparing surgery codes in data item RX Summ–Surg Prim Site 03-2022 [1290] used for cases diagnosed from 2003 to2022 and surgery codes used in the data item RX Summ–Surg Prim Site 2023 [1291] for cases diagnosed in 2023 or later.

Changes to the Breast, Lung, Colon, Thyroid, and Pancreas apply to cases diagnosed in 2024 or later.


2023: For cases diagnosed January 1, 2023 - December 31, 2023, The site-specific surgery codes are taken from Appendix C of the 2023 SEER Program Coding and Staging Manual, which is based on Appendix A of the ACoS STORE Manual -revised 2023.  The surgery codes are identical to STORE but the SEER appendix also contains supplementary annotations, including coding guidelines, solid tumor rules, EOD schemas, and additional instructions including site-specific codes for Neoadjuvant Therapy Treatment Effect. It can be found at: https://seer.cancer.gov/manuals/2023/appendixc.html

Surgery Codes Crosswalk 2023:  

When significant changes are made to the surgery codes, surgery code definitions, and/or instructions for assigning surgery codes for a site, a crosswalk is developed to assist with analyses and quality control reviews of surgery codes over time. They should not be used by registrars to directly code cancer cases.

These crosswalks are developed as an aid to anyone comparing surgery codes in data item RX Summ–Surg Prim Site 03-2022 [1290] used for cases diagnosed from 2003 to2022 and surgery codes used in the data item RX Summ–Surg Prim Site 2023 [1291] for cases diagnosed in 2023 or later.

Significant changes made to the Skin surgery codes apply to cases diagnosed in 2023 or later. A crosswalk for the Skin surgery codes was posted on 2/2/23. An update to the Skin Surgery codes was posted on 10/3/23. 


2022: For cases diagnosed January 1, 2022 - December 31, 2022, The site-specific surgery codes are taken from Appendix C of the 2022 SEER Program Coding and Staging Manual, which is based on Appendix A of the ACoS STORE Manual -revised 2022.  The surgery codes are identical to STORE but the SEER appendix also contains supplementary annotations, including coding guidelines, solid tumor rules, EOD schemas, and additional instructions including site-specific codes for Neoadjuvant Therapy Treatment Effect. It can be found at: https://seer.cancer.gov/archive/manuals/2022/appendixc.html


2021: For cases diagnosed January 1, 2021 - December 31, 2021, The site-specific surgery codes are taken from Appendix C of the 2021 SEER Program Coding and Staging Manual, which is based on Appendix A of the ACoS STORE Manual -revised 2021.  The surgery codes are identical to STORE but the SEER appendix also contains supplementary annotations, including coding guidelines, solid tumor rules, EOD schemas, and additional instructions including site-specific codes for Neoadjuvant Therapy Treatment Effect. It can be found at: https://seer.cancer.gov/archive/manuals/2021/appendixc.html


For cases diagnosed in 2018, 2019, or 2020: The site-specific surgery codes are taken from Appendix C of the 2018 SEER Program Coding and Staging Manual, which is based on Appendix B of the ACoS STORE Manual - revised 2018.  The surgery codes are identical to STORE but the SEER appendix also contains supplementary annotations, including the 2018 Solid Tumor Rules and EOD coding instructions.  It can be found at: SEER Appendix C

To download the 2018 STORE Manual, go to: https://www.facs.org/quality-programs/cancer/ncdb/call-for-data/cocmanuals

For diagnoses prior to January 1, 2003, use the ROADS surgery codes, which can be found at: http://seer.cancer.gov/manuals/AppendC.pdf